Current and historical daily PE Ratio for HZNP (
Horizon Therapeutics PLC
) from 2011 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Horizon Therapeutics PLC stock (HZNP) PE ratio as of Apr 24 2024 is 62.19.
More Details
Horizon Therapeutics PLC (HZNP) PE Ratio (TTM) Chart
Horizon Therapeutics PLC (HZNP) PE Ratio (TTM) Historical Data
View and export this data going back to 2011. Start your Free Trial
Total 1078
- 1
- 2
- 3
- 4
- 5
- 6
- 12
| Horizon Therapeutics PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-10-09 | 62.2 | 2023-08-04 | 53.5 |
| 2023-10-06 | 62.2 | 2023-08-03 | 52.9 |
| 2023-10-05 | 62.2 | 2023-08-02 | 53.0 |
| 2023-10-04 | 62.2 | 2023-08-01 | 53.3 |
| 2023-10-03 | 62.2 | 2023-07-31 | 53.6 |
| 2023-10-02 | 62.0 | 2023-07-28 | 53.4 |
| 2023-09-29 | 61.9 | 2023-07-27 | 53.3 |
| 2023-09-28 | 61.9 | 2023-07-26 | 53.4 |
| 2023-09-27 | 61.9 | 2023-07-25 | 53.6 |
| 2023-09-26 | 61.9 | 2023-07-24 | 53.7 |
| 2023-09-25 | 61.9 | 2023-07-21 | 54.1 |
| 2023-09-22 | 61.8 | 2023-07-20 | 54.5 |
| 2023-09-21 | 61.8 | 2023-07-19 | 55.6 |
| 2023-09-20 | 61.8 | 2023-07-18 | 55.6 |
| 2023-09-19 | 61.8 | 2023-07-17 | 55.6 |
| 2023-09-18 | 61.7 | 2023-07-14 | 55.6 |
| 2023-09-15 | 61.7 | 2023-07-13 | 55.5 |
| 2023-09-14 | 61.7 | 2023-07-12 | 55.4 |
| 2023-09-13 | 61.6 | 2023-07-11 | 55.1 |
| 2023-09-12 | 61.7 | 2023-07-10 | 54.9 |
| 2023-09-11 | 61.4 | 2023-07-07 | 54.9 |
| 2023-09-08 | 61.7 | 2023-07-06 | 54.9 |
| 2023-09-07 | 61.7 | 2023-07-05 | 55.1 |
| 2023-09-06 | 61.8 | 2023-07-03 | 55.1 |
| 2023-09-05 | 61.8 | 2023-06-30 | 55.0 |
| 2023-09-01 | 61.7 | 2023-06-29 | 55.2 |
| 2023-08-31 | 60.3 | 2023-06-28 | 55.1 |
| 2023-08-30 | 60.3 | 2023-06-27 | 64.6 |
| 2023-08-29 | 60.2 | 2023-06-26 | 64.5 |
| 2023-08-28 | 60.0 | 2023-06-23 | 64.5 |
| 2023-08-25 | 57.0 | 2023-06-22 | 63.8 |
| 2023-08-24 | 56.9 | 2023-06-21 | 63.9 |
| 2023-08-23 | 56.8 | 2023-06-20 | 63.8 |
| 2023-08-22 | 56.3 | 2023-06-16 | 63.9 |
| 2023-08-21 | 56.1 | 2023-06-15 | 63.7 |
| 2023-08-18 | 55.5 | 2023-06-14 | 63.3 |
| 2023-08-17 | 55.5 | 2023-06-13 | 62.9 |
| 2023-08-16 | 55.7 | 2023-06-12 | 62.8 |
| 2023-08-15 | 55.7 | 2023-06-09 | 62.4 |
| 2023-08-14 | 55.6 | 2023-06-08 | 62.5 |
| 2023-08-11 | 55.8 | 2023-06-07 | 62.5 |
| 2023-08-10 | 56.0 | 2023-06-06 | 62.8 |
| 2023-08-09 | 56.0 | 2023-06-05 | 62.7 |
| 2023-08-08 | 55.7 | 2023-06-02 | 62.9 |
| 2023-08-07 | 54.1 | 2023-06-01 | 63.1 |
Horizon Therapeutics PLC (HZNP) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Horizon Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : IE00BQPVQZ61
Description
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers